Do you want to read an article? Please log in or register.
Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-mutant Metastatic Breast Cancer
Breast Cancer
Related content
Breast Cancer
Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR-positive/HER2-negative metastatic breast cancer: Real-world data from the OPAL registry
Int J Cancer
Marschner P, Ringwald K, Thill M, Zahn MO, Welt A, Nusch A, Kaltenecker G, Rodemer Y, Hagen V, Schock C, Kruggel L, Kaiser-Osterhues A, Klein D, Haug N, Stickeler E, Harbeck N, Wöckel A, Marschner N, Decker T, OPAL Registry Group
doi: 10.1002/ijc.70433
SPECIAL REPORT
Breast Cancer
Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study
Breast Cancer
Recent treatment and survival trends in older versus younger women with HR-positive HER2-negative metastatic breast cancer in the real-life multicenter French ESME cohort
Eur J Cancer
Bouteiller F, Gourgou S, Bringuier M, Galvin A, Mailliez A, Bertrand N, Hung M, Frenel JS, Massard V, Bachelot T, Pflumio C, Gonçalves A, Levy C, Bosquet L, Jacot W, Delaloge S, Grinda T, Bellera C
doi: 10.1016/j.ejca.2025.116166
Breast Cancer
Real-world progression-free survival and overall survival in patients with HR(+)/HER2(-) advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study
Int J Cancer
Fasching PA, Brucker C, Decker T, Engel A, Göhler T, Jackisch C, Janssen J, Köhler A, Lüdtke-Heckenkamp K, Lüftner D, Marmé F, van Mackelenbergh M, Rautenberg B, Schmidt M, Weide R, Wimberger P, Kisseleff E, Pfister C, Quiering C, Roos C, Wöckel A
doi: 10.1002/ijc.70397
Lung, Respiratory and Thoracic Cancer
Real-world treatment and outcomes for EGFR WT advanced/metastatic non-squamous non-small cell lung cancer: pooled analysis from project LUMINATE-101
Oncologist
Girard N, Xu Q, Camidge DR, Baijal S, Ng S, Kamalakar R, Ratajczak C, Alhasani H, Crawford S, Karve S, Lu S
doi: 10.1093/oncolo/oyaf029
Lung, Respiratory and Thoracic Cancer
Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort
J Thorac Oncol
Illini O, Hund AC, Kopp HG, Moskovitz M, Mountzios G, Brueckl WM, Früh M, Leßmann ME, Christopoulos P, Stenzinger A, Thomas M, Gillis R, Peled N, Acker F, Addeo A, Charpidou A, Grohé C, Mauti L, Rothschild SI, Schmid S, Schumann C, Urban D, Wurm R, Ekman S, Skribek M, Glanemann F, Wiesweg M, Ackermann CJ, Agelaki S, Hoffknecht P, Jakopović M, Kern J, König D, Kostenzer K, Kropf-Sanchen C, Laack E, Lang D, Nagl L, Pall G, Reck M, Kian W, Allemann AT, Alt J, Araújo D, Bokas A, Hannah F, Julie KJ, Weinlinger C, de Langen AJ, Fergadis EG, Fountzilas E, Froesch P, Frost N, Griesinger F, Jordan F, Karanikiotis C, Kiesewetter B, Korantzis I, Machado AL, Economopoulou P, Pilz A, Reimann P, Rittmeyer A, Saad A, Samitas K, Schulmann K, Shah R, Stratmann JA, Taghizadeh H, Tammoscheit K, Tufman A, Weber JP, Wöll E, Valipour A, Overbeck TR, Hochmair MJ
doi: 10.1016/j.jtho.2026.103651
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
ESMO Open
Peters S, Salomonsen RJ, Diaz Perez I, Shcherbakova T, Wang A, Cai L, Sadow S, Liu SV
doi: 10.1016/j.esmoop.2025.106031
Genitourinary Cancer
Comparison of Real-World Outcomes between Patients with BRCA1/2-Positive and Homologous Recombination Repair-Negative Metastatic Castration-Sensitive Prostate Cancer
Adv Ther
Bilen MA, Burbage S, Rossi C, Khilfeh I, Diaz L, Wang Y, Pilon D, Brown G, Shore N, Lowentritt B, Lin DW
doi: 10.1007/s12325-025-03270-z
Genitourinary Cancer
PSA Absolute Value Versus PSA Response Rate: Which Is More Valuable for Estimating Survival Outcomes With ARPI Treatment for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Real-World Analyses?
Prostate
Shimomura T, Otsuka N, Urabe F, Muramoto K, Yanagisawa T, Fukuokaya W, Mori K, Tashiro K, Katsumi K, Takahashi H, Yoshihara K, Miyajima K, Imai Y, Iwatani K, Kayano S, Igarashi T, Murakami M, Tsuzuki S, Yamada H, Miki J, Kimura T, JIKEI YAYOI Collaborative Group
doi: 10.1002/pros.24885